The Institute for Clinical and Economic Review has published its assessment of JAK inhibitors for treating rheumatoid arthritis.
Studies show oral semaglutide is effective in treating type 2 diabetes. ICER's report will help insurance companies block access for patients in need.
In recent weeks, more doctors, patient advocates and health care policymakers have spoken about ICER's flawed reports, including former FDA Commissioner Dr. Scott Gottlieb.
The Institute for Clinical and Economic Review, which receives support from insurance companies, has begun its financial analysis of how two new SCD treatments, crizanlizumab and voxelotor, will affect insurance profits.
SSTs are considered game changers in medicine with the potential to cure rare, fatal or chronic diseases, such as Alzheimer’s disease.
Massachusetts state representatives, have introduced legislation that would block insurance companies, hospitals, health maintenance organizations, and the state’s Medicaid program, MassHealth, from using “quality-adjusted life years” in providing care to patients.
The Institute for Clinical and Economic Review will conduct an insurance profit analysis for two new additive therapies cardiovascular disease.
Their kids have a rare and fatal disease. ICER President Dr. Steve Pearson believes Duchenne moms shouldn't get a "vote" on their kids' treatment.
ICER. What is it? Who is it? Who put them in charge of my children’s health care? I ask this question – urgently – because Thursday, this group called ICER…
Citing its impact on “health care insurance costs,” the Institute for Clinical and Economic Review has issued its dreaded insurance profitability “alert” for two new treatments for peanut allergies. ICER’s report encourages insurance companies to deny coverage and impose substantial barriers for patients seeking access to the treatments.